Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04793737

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
27 (estimated)
Sponsor
Karolinska University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.

Detailed description

A phase II open-label multicenter trial evaluating response rate (RR) in patients receiving precision radiation (SBRT) to melanoma metastasis that have progressed on PD-1 inhibitor therapy. Patients will continue on PD-1 inhibitor therapy (pembrolizumab or nivolumab) for up to one year after completed precision radiation and will be followed-up for 24 months or until disease progression or death. The primary endpoint of the study is overall response rate (ORR) in non-irradiated lesions. The study will be conducted according to Simon´s two Stage minimax Design. Patients will be enrolled in two batches, first consisting of 13 patients. If no objective responses (complete response (CR) or partial response (PR)) are reported after the first stage, the study is interrupted early for futility. When the 13th patient is recruited, if there is at least one objective response in patient´s non-irradiated lesion(s), the recruitment can proceed into second stage. 14 more patients will then be included up to a total of 27 patients to determine ORR along with the 95% confidence interval. The test result is considered positive when at least 15% of the patients have a confirmed objective response.

Conditions

Interventions

TypeNameDescription
RADIATIONPrecision Radiation (SBRT)Precision radiation of melanoma metastases

Timeline

Start date
2021-03-08
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2021-03-11
Last updated
2025-03-05

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT04793737. Inclusion in this directory is not an endorsement.